DSIP (20 mg Vial) Dosage Protocol

Dosing & Reconstitution Overview

DSIP (Delta Sleep-Inducing Peptide) is a short nonapeptide that has been studied as a neuromodulator of the sleep-wake cycle and the stress response. The figures below are compiled strictly for laboratory and educational reference — they describe how the compound was handled and dosed across published research, not a recommendation for use in humans or animals.

For a 20 mg vial, adding 4.0 mL of bacteriostatic water yields a concentration of 5 mg/mL (5,000 mcg/mL). At that concentration, every 0.01 mL drawn on a U-100 insulin syringe equals 1 unit and delivers 50 mcg of material, which keeps the arithmetic clean across the low microgram titration steps used in the sleep model.

Standard (Gradual) Titration Schedule

The gradual schedule mirrors the slow ramp used in the published evening-dosing model, where the daily amount is stepped up week by week to gauge tolerability before settling into a maintenance band.

Reconstitution Steps

1. Let the sealed lyophilized vial and the bacteriostatic water reach room temperature, then wipe both stoppers with an alcohol swab.
2. Draw 4.0 mL of bacteriostatic water and inject it slowly down the inside wall of the vial — never directly onto the powder pellet.
3. Swirl gently until fully dissolved. Do not shake; aggressive agitation can shear the peptide.
4. The solution should be clear and colourless. Label the vial with the concentration (5 mg/mL) and the reconstitution date.
5. Store upright under refrigeration between uses and draw subsequent volumes with a fresh sterile syringe each time.

Advanced (Maintenance) Schedule

Because the research range tops out around 300 mcg daily, the "advanced" track is less an escalation than a steady maintenance plan that holds the upper band and standardises the evening timing window rather than pushing the dose higher.

Supplies Needed

• DSIP vials (20 mg): ~1 vial for an 8-week run at the maintenance band; ~1–2 vials for a 12-week run depending on the daily dose.
• Insulin syringes (U-100, 30–50 unit): ~56 for an 8-week daily schedule; ~84 for 12 weeks (one fresh syringe per draw).
• Bacteriostatic water (10 mL): one bottle covers a single 20 mg vial (4 mL used) with margin to spare.
• Alcohol swabs: a 100-count box comfortably covers an 8–12 week daily schedule.

Protocol Overview

• Research goal: model sleep-wake regulation and HPA-axis stress modulation via a delta-wave-promoting neuropeptide.
• Schedule: once-daily subcutaneous administration in the evening in the published model.
• Dose band: 100–300 mcg daily, ramped over the first weeks.
• Fill: 20 mg lyophilized, reconstituted to 5 mg/mL with 4 mL diluent.
• Storage: −20 °C dry; 2–8 °C once reconstituted.

Dosing Protocol Notes

• Begin at the 100 mcg step and hold each level for about one week before stepping up.
• Keep administration in a fixed evening window — roughly 30–60 minutes before the rest period — for steady exposure modelling.
• Settle into the 250–300 mcg maintenance band once tolerability is established.
• Keep the same daily cadence; the peptide's short half-life means timing consistency matters more than dose stacking.

Storage Instructions

Keep sealed lyophilized vials at −20 °C, protected from light, where stability extends for many months. Once reconstituted, refrigerate at 2–8 °C and use within about four weeks. Allow refrigerated solution to warm slightly before drawing, avoid repeated freeze-thaw cycles, and aliquot if a vial will be sampled many times.

Important Handling Notes

• Use a sterile syringe for every draw and never re-enter the vial with a used needle.
• Rotate sampling/handling technique to keep the stopper intact.
• A 30- or 50-unit syringe improves accuracy when measuring the small microgram volumes involved.
• Document each draw — date, volume, remaining material — for reproducibility.

How DSIP Works

DSIP is a small endogenous nonapeptide first isolated for its ability to promote delta-wave (slow-wave) activity on EEG recordings, which is why it is characterised as a neuromodulator of the sleep-wake cycle. It crosses the blood-brain barrier and is thought to enhance inhibitory neuronal signalling, shifting EEG patterns toward deeper sleep stages. Beyond sleep, it appears to dampen the stress response by attenuating ACTH and corticosterone release, implicating it in hypothalamic-pituitary-adrenal (HPA) axis regulation. Its short circulating half-life is the practical reason the research model favours consistent evening dosing rather than infrequent larger doses.

Reported Benefits & Side Effects

Benefits observed in research

• Improved sleep quality with longer slow-wave (delta) sleep duration in EEG studies.
• Potential normalisation of disrupted sleep architecture in chronic insomnia models.
• Signals for stress reduction and mood support attributed to HPA-axis modulation.
• A notably wide safety margin — animal studies reported no lethal dose even at very high exposures.

Side effects reported

• Generally mild and transient effects, most often occasional headache or nausea.
• Occasional minor injection-site reactions such as redness or itching.
• Overall the literature describes a favourable tolerability profile relative to dose.

Supporting Lifestyle Factors (Research Context)

• Consistent sleep-wake timing to reinforce circadian rhythm in the study designs.
• Reduced evening caffeine and screen exposure as standard sleep-hygiene controls.
• A dark, cool sleep environment to support natural melatonin signalling.
• Stress management practices and regular physical activity as background variables.

Injection Technique (Reference Only)

• Clean the vial stopper and the site with alcohol swabs and let them dry.
• Pinch a skinfold and insert subcutaneously at a 45–90° angle depending on needle length; aspiration is not required for subcutaneous work.
• Inject slowly and steadily; the volumes here are small (well under 0.1 mL).
• Rotate sites systematically across the abdomen, thighs and upper arms, and dispose of sharps in an approved container.

References

Related Protocols